Cadrenal Therapeutics (NASDAQ: CVKD)
$12.28
(-1.7%)
-$0.22
Price as of July 15, 2025, 1:12 p.m. ET
Cadrenal Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cadrenal Therapeutics Company Info
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.